Takeda Pharmaceutical Company Limited is a prominent global biopharmaceutical entity dedicated to the discovery, development, manufacturing, commercialization, and out-licensing of pharmaceutical products. ...
Takeda (NYSE: TAK) is one of the world’s large, innovation-focused biopharmaceutical companies, with roots dating back to 1781 in Japan. The company’s purpose centers on improving health outcomes for patients through an R&D-driven model designed to translate scientific discovery into therapies that can be manufactured reliably at scale and commercialized ...Takeda (NYSE: TAK) is one of the world’s large, innovation-focused biopharmaceutical companies, with roots dating back to 1781 in Japan. The company’s purpose centers on improving health outcomes for patients through an R&D-driven model designed to translate scientific discovery into therapies that can be manufactured reliably at scale and commercialized globally. Takeda’s business spans the full lifecycle of drug development—from early discovery and clinical development to manufacturing, regulatory work, market access, and long-term commercialization—as well as out-licensing/partnering to expand reach and pipeline potential.
From a product and therapeutic-area perspective, Takeda maintains a broad portfolio addressing multiple high-need segments. The company’s marketed medicines include treatments for digestive disorders (gastroenterology), rare diseases, plasma-derived therapies, oncology, and neurological conditions. Many of these therapies are branded and supported by specialty commercialization efforts, including field medical activities and patient support services that are typical in specialty pharma. Examples of brand names referenced in the source description include Entyvio, Gattex/Revestive, Alofisel, Dexilant, Natpara, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Hyqvia, Cuvitru, Exkivity, and Adcetris, among others.
Takeda’s global footprint is substantial, reflecting both regional commercialization needs and the operational complexity of specialty manufacturing and supply chain management. It serves markets across Japan, the United States, Europe, Canada, Latin America, Russia, and other Asian and worldwide regions. In the United States, Takeda has a major presence and an R&D hub in the Cambridge, Massachusetts area, supporting the company’s ongoing innovation agenda.
In addition to in-house R&D, Takeda’s strategy includes collaboration and licensing arrangements with research institutions and biopharmaceutical partners. These relationships can contribute pipeline assets, complementary platforms, and geographic or therapeutic expansion. The company’s approach often combines internal development with external innovation to reduce development risk and accelerate access to promising science.
Operationally, costs in biopharmaceutical businesses are driven by R&D and clinical trials, specialized manufacturing capacity, quality systems, regulatory compliance, and post-marketing obligations. Takeda’s business model also involves considerable working-capital and supply-chain management demands typical of specialty pharma (including forecasting demand, handling biologics/plasma-derived product constraints, and managing inventory efficiently to support continuity of supply). On the financial side, the company’s scale—tens of thousands of employees and a large market capitalization—supports a diversified revenue base across products and geographies, while ongoing investment in research maintains a pipeline to sustain future growth.
Key leadership in the provided data lists Julie So-Young Kim as CEO (with prior reporting indicating a transition from the earlier CEO-elect period). Takeda’s long-term outlook is strongly tied to its ability to advance clinical-stage candidates, protect and extend the value of its current product portfolio, and successfully integrate partnered assets into its development and commercialization pipeline.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$4777.5B
+4.3%
+9.4%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$203.3B
+88.4%
+557.1%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
+51.1%
-22.1%
+36.6%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
+12.0%
+60.4%
+287.1%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
+4.3%
+80.7%
+517.6%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$626.8B
-7.5%
+628.3%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
+13.1%
-11.3%
+565.5%
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
62.8%
-3.5%
+4.1%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
1.27x
+26.5%
-10.4%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
Christopher David O'Reilly: [Interpreted] Thank you very much for joining us today despite a very busy schedule for the FY '26 Q1 earnings announcement by Takeda. My name is O'Reilly, and I'm the Head of IR. I'll be facilitating the discussion today. Thank you for this opportunity. And first of all, allow me to explain about the language setting. [Operator Instructions] Before starting, I'd like to remind everyone that we will be discussing forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those discussed today. The factors that could cause our actual results to differ materially are discussed in our most recent Form 20-F and in our other SEC filings. Please also refer to the important notice on Page 2 of the presentation regarding forward-looking statements and our non-IFRS financial measures, which will be also discussed during this call. Definitions of our non-IFRS measures and reconciliations with comparable IFRS financial statements are introduced in the appendix of the presentation. Now we would like to start the presentation. We have President and CEO, Julie Kim; Chief Financial Officer, Milano Furuta; and President, R&D, Andy Plump. They will do the presentation, which will be followed by the Q&A session. We will get started. Julie, please go ahead.
Julie Kim: Thank you, Chris. Thank you for joining us for today's earnings call focused on the first quarter of fiscal year 2026. We delivered a solid start to the fiscal year, and our performance this quarter demonstrates steady progress against our strategic priorities, keeping us firmly on track to achieve our full year guidance. These achievements reflect our continued execution against the 2-Horizon strategic road map we shared last quarter, which will position us for accelerated growth in the years ahead to expand impact for patients and set the stage for sustained value creation. Today, I will outline this quarter's progress against our priorities. Financially, we delivered a solid quarter and made steady progress against our fiscal year '26 priorities. In the first quarter, core revenue declined slightly at 0.5% at constant exchange rate, or CER, in line with our expectations as momentum across our core in-line brands and existing new launch brands largely offset anticipated headwinds in our mature portfolio. Core operating profit declined 0.5% year-over-year at CER, reflecting the continued investment behind our upcoming launches and exciting late-stage pipeline, which we are partially offsetting by savings generated through our transformation program. And core EPS was JPY 154, a decrease of 11.8% at CER, mainly due to a favorable tax position in the prior year. Milano will walk you through the financial dynamics in more detail shortly, but the key takeaway is that we are well on track towards our full year guidance. This quarter, we had strong execution across all Horizon One priorities. …
